I

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Vice President Corporate Controller

Financial AccountingPosted on Nov 10
Full-timeRemote in USA$290k - $350k /yr

About the Job

Requirements

  • A bachelor's degree in Accounting and an active or inactive CPA are required.
  • At least 10 years of progressive accounting experience, including Big 4 public accounting and public-company industry experience, is required.
  • Direct, hands-on gross-to-net accounting experience at a commercial-stage pharmaceutical or biotechnology company, including establishing or managing gross-to-net reserves and accruals, is required.
  • Strong knowledge of U.S. GAAP, particularly ASC 606 and ASC 330, SEC reporting requirements, and SOX 404 compliance, including internal control design, is required.
  • The candidate must demonstrate an ability to lead a close process and manage and develop staff.
  • The candidate must be based on the east coast.
  • The candidate must have experience with Oracle NetSuite as an end user or administrator.

Responsibilities

  • Design, implement, and own gross-to-net revenue accounting for the first commercial product, including reserves for chargebacks, commercial and government rebates, distribution and data fees, co-pay assistance, returns, and prompt-pay discounts.
  • Develop audit-ready gross-to-net estimation methodologies, roll-forwards, and true-up processes, applying ASC 606 variable consideration principles.
  • Partner with Market Access, Trade, and Government Pricing to align contract terms, channel data, and government pricing calculations, including AMP, Best Price, ASP, and Non-FAMP, with accounting.
  • Establish inventory accounting and costing under ASC 330, including pre-launch inventory capitalization, standard costing, CMO/3PL reconciliations, and excess and obsolescence reserves.
  • Lead the monthly, quarterly, and annual close, including clinical trial accruals, stock-based compensation, leases, and other technical areas.
  • Prepare and review Forms 10-Q and 10-K, footnotes, and supporting schedules in partnership with the CFO and SEC reporting resources.
  • Design and maintain a SOX-compliant internal control environment, scaling controls for new commercial processes such as order-to-cash, gross-to-net, inventory, and procure-to-pay.
  • Serve as primary liaison with external auditors for quarterly reviews and the annual audit, and prepare technical accounting memoranda for new transactions and commercial arrangements, using external consultants as needed.
  • Support selection and implementation of a commercial-ready ERP and related systems, including gross-to-net/revenue management and 3PL integrations.
  • Build, lead, and develop a high-performing accounting team; manage outsourced accounting partners; and partner with FP&A on budgeting, forecasting, and launch-related financial analysis.

Desired Qualifications

  • Experience with Oracle NetSuite, ideally including a key role in a NetSuite implementation at a life sciences company preparing for commercialization.
  • Experience with Workiva for SEC reporting, including 10-Q/10-K reporting and XBRL tagging.
  • Experience with a product launch or building commercial accounting processes from the ground up.
  • Familiarity with government pricing, the Medicaid Drug Rebate Program, 340B, and specialty distribution models.
  • Experience with gross-to-net/contract management systems such as Model N, IntegriChain, or Revitas.

About the Company

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Immunic Therapeutics develops oral therapies for chronic inflammatory and autoimmune diseases and is in clinical-stage development. Its lead candidate, vidofludimus calcium (IMU-838), is an oral small molecule that activates the Nurr1 receptor to protect nerve cells and inhibits DHODH to calm overactive immune responses; its pipeline also includes IMU-856, a SIRT6 modulator aimed at restoring intestinal barrier function, with IMU-381 in preclinical GI programs. The company emphasizes oral, small-molecule drugs with dual actions and pursues partnerships or licensing for commercialization rather than relying on near-term product revenue. Its goal is to advance its drug candidates through clinical trials toward commercialization, potentially via collaborations with larger pharma companies.

Company size
51-200
Company stage
IPO
Headquarters
New York City, New York
Founded
2016

Recently Posted Jobs

Explore more opportunities at Immunic Therapeutics

See more jobs